SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 1, 2002; DOI 10.1182/blood-2002-06-1672. This Article Full Text (PDF) All Versions of this Article: 2002-06-1672v1 100/13/4367    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by DiNubile, M. J Articles by Antin, J. H Search for Related Content PubMed PubMed Citation Articles by DiNubile, M. J Articles by Antin, J. H Social Bookmarking                   What's this? Submitted June 7, 2002 Accepted July 19, 2002 Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation Mark J DiNubile*, Thomas P Stossel, Olof C Ljunghusen, James L M Ferrara, and Joseph H Antin * Corresponding author; email: mark_dinubile{at}merck.com. The idiopathic pneumonia syndrome (IPS) represents a common and often fatal complication of hematopoietic stem cell transplantation (HSCT). Gelsolin is a highly conserved actin-binding protein normally present in plasma that may serve a basic physiological role in limiting acute lung injury of diverse etiologies. We hypothesized that depletion of circulating gelsolin following HSCT might play a permissive role in the pathogenesis of IPS. Plasma gelsolin levels were measured by immunoblotting in frozen samples obtained weekly from 24 patients undergoing allogeneic HSCT. Patients with and without IPS were similar with respect to age, diagnosis, histocompatibility differences between donor and recipient, and conditioning regimen. Mean gelsolin levels in the 9 patients with rapidly fatal IPS were significantly lower than patients without this complication by week 3 post-HSCT [101 ± 61 vs. 221 ± 54 mg/L; p = 0.0002]. Seven of the 8 patients (88%) with gelsolin levels <100 mg/L in the first month after HSCT died from IPS within 3 months; conversely, gelsolin levels fell <100 mg/L in 7 of the 9 patients (78%) who died from IPS within 3 months of HSCT (p = 0.0007). These findings suggest that gelsolin levels shortly after allogeneic HSCT can predict the later development of fatal IPS. Gelsolin replacement in selected transplant patients may offer a novel strategy to prevent or reverse IPS. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: P.-S. Lee, K. Sampath, S. A. Karumanchi, H. Tamez, I. Bhan, T. Isakova, O. M. Gutierrez, M. Wolf, Y. Chang, T. P. Stossel, et al. Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1140 - 1148. [Abstract] [Full Text] [PDF] M. J. DiNubile Plasma gelsolin: in search of its raison d'etre. Focus on "Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin" Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1240 - C1242. [Full Text] [PDF] T. M. Osborn, C. Dahlgren, J. H. Hartwig, and T. P. Stossel Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1323 - C1330. [Abstract] [Full Text] [PDF] P. Marik, S. Pastores, D. Annane, R. Speich, C. Schmid, R. Stocker, H. Okamoto, M. J. DiNubile, K. P. Steinberg, L. D. Hudson, et al. Corticosteroids in ARDS. N. Engl. J. Med., July 20, 2006; 355(3): 316 - 317. [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020